ライフサイエンスコーパス: CRTH2

1 ) and PGD2 receptor 2 (DP2, sometimes termed CRTH2).

2 -homologous molecule expressed on Th2 cells (CRTH2).

3 -homologous receptor expressed on Th2 cells (CRTh2).

4 molecule expressed on type 2 T-helper cells (Crth2).

5 receptor homologous molecule on T(H)2 cells (CRTH2).

6 D30, TNFR2, ICOS, CCR4, and CD200R1 than for CRTH2.

7 le dual antagonist of human D-prostanoid and CRTH2.

8 ession of the ST2 receptor in the absence of CRTH2.

9 c IL-33 treatment was partially dependent on CRTH2.

10 further investigate the in vivo function of CRTH2.

11 ant receptors such as CCR4, CCR5, CXCR6, and CRTH2.

12 ion of CXCR3 and down-regulation of CCR4 and CRTH2.

13 a nonconserved mechanism of lipid action on CRTH2.

14 tinal stem, goblet, and tuft cells expressed CRTH2.

15 cells, but may decrease their expression of CRTh2.

16 y for the human, monkey, dog, rat, and mouse CRTH2, 2) interacts with CRTH2 in a reversible manner, 3

17 st on recombinant and endogenously expressed CRTH2, 5) demonstrates good oral bioavailability and met

18 Receptor Homologous to the T helper 2 cell (CRTH2), a G protein-coupled receptor, present on a subse

19 -homologous molecule expressed on TH2 cells (CRTH2), a receptor for prostaglandin D(2) (PGD(2)), is e

20 -homologous molecule expressed on Th2 cells (CRTH2), a receptor for the bioactive lipid prostaglandin

21 ith amniocytes and myocytes transfected with CRTH2 acting as a positive control in flow cytometry stu

22 re CRTh2 as well as IL-5 and IL-13 following CRTh2 activation than Th2 cells treated with GC alone.

23 eptors to amplify the biological response to CRTH2 activation.

24 This effect was mimicked by the selective CRTH2 agonist 13,14-dihydro-15-keto-PGD(2), inhibited by

25 effect of PGD2 was mimicked by the selective CRTH2 agonist 13,14-dihydro-15-keto-PGD2 but not by the

26 The CRTH2 agonist had no effect on NF-kappaB activity in amn

27 The effect of a small molecule CRTH2 agonist on NF-kappaB activity in human cultured am

28 ILC2 activation through CRTH2 also upregulated the expression of IL-33 and IL-25

29 ic IgE correlated with surface expression of CRTH2 and CD200R (both p .05).

30 oteins abolishes the Ca(2+) response to both CRTH2 and DP agonists, whereas inhibition of Galpha(i) p

31 We show that CRTH2 and DP receptors modulate one another's signaling

32 The cross-talk of CRTH2 and DP receptors was investigated by using both a

33 on of the profibrotic BRP-39 receptor Ptgdr2/Crth2 and expression of the profibrotic markers Lgals3,

34 LC2s) are identified by coupled detection of CRTH2 and IL7Ralpha on lineage negative (Lin(-)) cells.

35 + subset of ILC3 expresses the PGD2 receptor CRTH2 and is the source of the increased IL-22.

36 bly, targeting astrocytic CHI3L1 or blocking CRTH2 and its downstream effectors substantially restore

37 ient in the prostaglandin D2 (PGD2) receptor CRTH2 and mice with CRTH2 deficiency only in nonhematopo

38 d hyper-activated through the interaction of CRTH2 and NKp30 with elevated tumour-derived PGD2 and B7

39 n ILCs that express CD117 and CD127 but lack CRTH2 and NKp44 have been shown to contain precursors of

40 ggesting that the stimulation is mediated by CRTH2 and not DP.

41 rs533116 and allergic asthma, expression of CRTh2 and Th2 cytokine production.

42 ts had higher % of CD4(+) T cells expressing CRTh2 and worse FEV(1) during exacerbation compared with

43 -homologous molecule expressed on Th2 cells (CRTH2) and has been detected at high concentrations at s

44 ogous molecule expressed on TH2 lymphocytes (CRTH2) and PGD(2) receptor 1 (DP1).

45 omologous molecule expressed on T(H)2 cells (CRTH2), and D-type prostanoid (DP) receptor.

46 ogous molecule expressed on Th2 lymphocytes (CRTh2), and phosphodiesterase (PDE)-4 inhibitors.

47 between vasoactive intestinal peptide (VIP), CRTH2, and eosinophil recruitment.

48 erein we describe the discovery of the novel CRTh2 antagonist 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro

49 as well as X-hydroxy-naphthoyl analogues of CRTh2 antagonist 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro

50 d on the discovery of the recently disclosed CRTh2 antagonist 2-(2-benzoyl-3,4-dihydro-1H-pyrido[4,3-

51 OC000459 is a selective CRTH2 antagonist and would be expected to suppress eosin

52 estigate the efficacy and safety of the oral CRTH2 antagonist BI 671800 (50, 200, and 400 mg twice da

53 ) synthase (HPGDS) inhibitor KMN698, and the CRTH2 antagonist CAY10471 on human ILC2s were determined

54 The CRTH2 antagonist CAY10595 improved, whereas the DP antag

55 Slow CRTh2 antagonist dissociation could provide increased re

56 The CRTH2 antagonist OC000459 has previously been demonstrat

57 inhibited phospho-65 in PBMC'S, however the CRTH2 antagonist was not able to attenuate this effect.

58 C50 = 6 nM), selective, and orally available CRTh2 antagonist.

59 -yl}acetic acid (MK-7246), a novel synthetic CRTH2 antagonist.

60 ctivated human mast cells and inhibited by a CRTH2 antagonist.

61 (1), a diazine indole acetic acid containing CRTH2 antagonist.

62 An 8-week treatment with the CRTH2-antagonist, OC000459, exerts modest, but significa

63 ation and highlight the potential utility of CRTH2 antagonists in the treatment of allergic diseases.

64 ,14-dihydro-15-keto-PGD(2), inhibited by the CRTH2 antagonists ramatroban and TM30089, and not observ

65 aglandin D synthase, respectively, or use of Crth2 antagonists recapitulated the proinflammatory phen

66 we provide the detailed mechanism behind how CRTH2 antagonists represent promising therapeutic tools

67 All CRTh2 antagonists tested inhibited PGD2-stimulated human

68 3-acetic acids that are potent and selective CRTH2 antagonists that possess good oral bioavailability

69 New classes of CRTH2 antagonists, the pyridazine linker containing indo

70 omologous molecule expressed on T(H)2 cells (CRTH2) are implicated in asthma pathogenesis.

71 ls expressing the prostaglandin D2 receptor (CRTH2) are TH2 central memory T cells, characterized by

72 pes of granulocyte subsets with emergence of CRTH2 as a disease biomarker.

73 ted Th2 cells exhibited less apoptosis, more CRTh2 as well as IL-5 and IL-13 following CRTh2 activati

74 Similarly, there were lower proportions of CRTh2(+) basophils expressing surface CD203c(bright) (al

75 Proportions of CD63(+) and CD203c(bright)CRTH2(+) basophils were decreased following LPP treatmen

76 Proportions of allergen-stimulated DAO(+)CRTh2(+) basophils were higher in participants in the SC

77 Blocking this CHI3L1/CRTH2/beta-catenin cascade restores neurogenesis and imp

78 evaluate the structural features that confer CRTH2 binding selectivity, structure-activity relationsh

79 Here, we report a crystal structure of human CRTH2 bound to a PGD(2) derivative, 15R-methyl-PGD(2) (1

80 contribute to adaptive type 2 immunity; thus CRTH2 bridges the innate and adaptive pathways in human

81 at IL-5 and IL-13 were expressed not only by CRTH2(+) but also by CRTH2(-)IL7Ralpha(+) and CRTH2(-)IL

82 Ligand-dependent activation of Crth2 by 13,14-dihydro-15-keto-prostaglandin D(2) increa

83 th more eosinophils and higher expression of CRTh2 by both CD4(+) T cells and eosinophils (P < 0.05).

84 In addition to PGD2, CRTH2 can be activated by indomethacin, a nonselective c

85 lls (ILC2) include IL-5- and IL-13-producing CRTh2(+)CD127(+)cells that are implicated in early prote

86 RTH2(+)CD161(-)), and T(H)2A (CCR6(-)CXCR3(-)CRTH2(+)CD161(+)CD27(-)) cells.

87 6(-)CXCR3(-)CRTH2(-)), T(H)2 (CCR6(-)CXCR3(-)CRTH2(+)CD161(-)), and T(H)2A (CCR6(-)CXCR3(-)CRTH2(+)CD

88 However, the cytokine profiles of these CRTH2+CD161+ (peTh2) memory CD4+ T cells are markedly di

89 CRTH2+CD161+ (peTh2) memory CD4+ T cells were significan

90 fined by specific surface markers and termed CRTH2+CD161+ (peTh2) memory CD4+ T cells.

91 pheral blood peTh2 cells (CD3+CD4+CD27-CD49d+CRTH2+CD161+) were profiled by intracellular cytokine fl

92 d transcriptionally distinct, marked by high CRTH2/CD161, low CD27, IL-5 production, and gene enrichm

93 Infiltrated CRTH2+CD4+ TH2 effector memory T cells in skin lesion of

94 CRTH2+CD4+ TH2 memory cells activated by TSLP-DCs underg

95 etin (TSLP) can induce a robust expansion of CRTH2+CD4+ TH2 memory cells, while maintaining their cen

96 educed IL-13 released from PBMCs and CD3+CD4+CRTh2 cells.

97 e was associated with a higher proportion of CRTh2(+) cells during Th2 differentiation as well as mor

98 in effector memory CD4 T cells that include CRTH2(+) cells through IL-4 and TCR-independent pathways

99 ypic ILC2 characteristics, lineage(-)CD127(+)CRTH2(+) cells, responded to IL-33 and produced large qu

100 subjects, the peanut-specific Th2 (CD154(+) CRTh2(+) ) cells expressed more CD200R than the non-alle

101 than the non-allergen-specific Th2 (CD154(-) CRTh2(+) ) cells.

102 CRTh2 (chemoattractant-receptor homologous molecule expr

103 andin D2 (PGD2) receptor CRTH2 and mice with CRTH2 deficiency only in nonhematopoietic cells exhibite

104 into IL-33-treated recipients, wild-type and CRTH2-deficient ILC2s accumulated equally in the recipie

105 ially accumulated in the lungs compared with CRTH2-deficient ILC2s following transfer into IL-33-trea

106 ies suggested that defective accumulation of CRTH2-deficient ILC2s in response to IL-33 was due to al

107 CRTH2-deficient small intestinal organoids showed enhanc

108 These data suggest that CRTH2-dependent effects lie downstream of IL-33, directl

109 kine production in human Th2 cells through a CRTH2-dependent mechanism in the absence of any other co

110 ILC2 activation and IT2IR were mediated via CRTH2-dependent mechanisms.

111 helminth infection or in organoids, PGD2 and CRTH2 down-regulated intestinal epithelial Il13ra1 expre

112 xpression of integrin CD11b, and Th2-related CRTH2 downregulation in eosinophils and basophils establ

113 Therefore the CRTH2/DP heteromer might not only represent a functional

114 one another's signaling properties and form CRTH2/DP heteromers without altering their ligand-bindin

115 dent activation of SOCE could be mediated by Crth2 during inflammation.

116 studies present a novel regulatory role for Crth2 during inflammatory response in macrophages.

117 ) T cells and % of CD4(+) T cells expressing CRTh2), eosinophils and innate lymphoid cells (ILC2).

118 ant receptor homolog expressed on Th2 cells (CRTH2)-expressing CD4(+) and CD8(+) T cells decreased si

119 After 21 days of altitude therapy, CRTH2-expressing ILC2, CD4(+) and CD8(+) T cells and Tre

120 the Crth2 receptor in macrophages that lack Crth2 expression [knockout (KO)].

121 We investigated DP and CRTH2 expression and function during human and murine ul

122 e 2 immune response, corrected the increased CRTH2 expression and its dysregulated functions.

123 It is shown that CRTH2 expression by eosinophils from allergic rhinitis (

124 DP and CRTH2 expression changed in leukocytes of patients with

125 Endogenous CRTH2 expression in amniocytes, myocytes and peripheral

126 those cells that remained had higher surface CRTH2 expression than did the cells from subjects not ta

127 ous molecule expressed on T(H)2 lymphocytes (CRTH2) expression and T(H)2 cytokine production--are spe

128 ometry regarding levels of CD23, CD44, CD54, CRTH2, FOXP3, and galectin-10.

129 rt that function to capture lipid ligands of CRTH2 from the lipid bilayer.

130 molecule expressed on T(H)2 cells-positive (CRTH2(+)), hematopoietic prostaglandin D synthase-positi

131 or psoriasis, which uniquely harbored CD3(+)CRTH2(+) IL-13 expressing "T(H)2A" cells, or strong type

132 ls of IL-5 and IL-13 were confined to HPGDS+ CRTH2+IL-17RB+FFAR3+CD4+ T8 effector Th2 cells.

133 f both ILC2s (prostaglandin D(2) receptor 2; CRTH2, IL-5, and IL-13) and ILC3s (c-kit and IL-17A) tha

134 e expressed not only by CRTH2(+) but also by CRTH2(-)IL7Ralpha(+) and CRTH2(-)IL7Ralpha(-) (double-ne

135 RTH2(+) but also by CRTH2(-)IL7Ralpha(+) and CRTH2(-)IL7Ralpha(-) (double-negative [DN]) human blood

136 Type 2 cytokine production by CRTH2(-)IL7Ralpha(-) innate lymphoid cells (ILCs) is unk

137 We sought to identify CRTH2(-)IL7Ralpha(-) type 2 cytokine-producing ILCs and

138 Transcriptomic analysis of CRTH2, IL7Ralpha, and DN ILCs confirmed the expression o

139 Although subsets of human CRTh2(+)ILC2 differentially express CD117 (c-kit recepto

140 L7Ralpha and DN ILCs were similar to that of CRTH2 ILCs in the blood and lung.

141 dog, rat, and mouse CRTH2, 2) interacts with CRTH2 in a reversible manner, 3) exhibits high selectivi

142 e sought to determine the role of PGD(2) and CRTH2 in human ILC2s and compare it with that of the est

143 In this study we show a novel function of CRTH2 in mediating an inhibitory effect of PGD(2) on the

144 The cellular distribution of CRTH2 in non-immune cells has not been extensively resea

145 nt study was to determine the involvement of CRTH2 in promoting nasal and ocular symptoms in allergic

146 irst evidence of association between VIP and CRTH2 in recruiting eosinophils.

147 its role in allergy and asthma, the role of Crth2 in the resolution of inflammation, to mediate the

148 However, the function of CRTH2 in these cells is unclear.

149 PGD(2) binding to CRTH2 induced ILC2 migration and production of type 2 cy

150 We find that the DP receptor amplifies the CRTH2-induced Ca(2+) release from intracellular stores a

151 However, CRTH2 internalization occurs independently of the DP rec

152 CRTH2 internalized upon treatment with PGD2 and 11-dehyd

153 CRTH2 is a G-protein-coupled receptor that mediates the

154 ory function of CRTH2 is well recognized and CRTH2 is hence considered an important emerging pharmaco

155 In conclusion, CRTH2 is not expressed on human amniocytes or myocytes a

156 on blood leukocytes is downregulated in UC, CRTH2 is present in colon tissue, where it may contribut

157 CRTH2 is the only member of the prostanoid receptor fami

158 Although the proinflammatory function of CRTH2 is well recognized and CRTH2 is hence considered a

159 molecule expressed on T-helper type 2 cells (CRTH2) is a G protein-coupled receptor that has been rep

160 -homologous molecule expressed on Th2 cells (CRTH2) is a G protein-coupled receptor that mediates the

161 t receptor-homologous molecule on Th2 cells (CRTH2) is a prostaglandin D(2) (PGD(2)) receptor, expres

162 homologous molecule expressed on Th2 cells (CRTH2), is less well defined.

163 The PGD2 receptor, CRTH2, is expressed on basophils, eosinophils, and Th2 l

164 genes, including Tnf-alpha, was observed in Crth2 KO cells.

165 itulated the proinflammatory phenotype as in Crth2 KO cells.

166 is may be mediated by elevated expression of CRTh2, leading to higher numbers of circulating eosinoph

167 re associated with higher PGD(2), HPGDS, and CRTH2 levels.

168 o investigate the structural determinants of CRTH2 ligand binding, we performed site-directed mutagen

169 e exploited for the development of selective CRTH2 ligands.

170 Western blot demonstrated a novel CRTH2-mediated cytosol-to-membrane translocation of PKC-

171 alpha(i) proteins selectively attenuates the CRTH2-mediated response but not the DP signal.

172 acologic blockade of the DP receptor hinders CRTH2-mediated signal transduction.

173 CRTH2 mediates activation of Th2 cells, eosinophils and

174 ortant and potent activator of ILC2s through CRTH2 mediating strong proallergic inflammatory response

175 and co-localization between VIP peptide and CRTH2 molecules.

176 CRTH2 mRNA and IHC values were highest in patients with

177 Th2 cells, eosinophils and CRTh2 mRNA correlated with clinical characteristics asso

178 Although CRTH2 mRNA was detected in amniocytes and myocytes, CRTH

179 ramatroban and TM30089, and not observed in CRTH2-negative T cells.

180 The decrease of CRTH2 on blood eosinophils clearly correlated with disea

181 Although expression of CRTH2 on blood leukocytes is downregulated in UC, CRTH2

182 nimal species, 6) yields ex vivo blockade of CRTH2 on eosinophils in monkeys and sheep, and 7) signif

183 with PGD(2), illustrating that activation of CRTH2 only inhibits apoptosis induced by cytokine depriv

184 higher expression of the TH2 surface marker CRTH2 (P = .04) and lower expression of the TH1 marker C

185 These data show that the PGD2-CRTH2 pathway negatively regulates the Type 2 cytokine-d

186 The IL-33-ST2 and the PGD(2)-CRTH2 pathways have both been implicated in promoting IL

187 ex interactions between the IL-33 and PGD(2)-CRTH2 pathways that regulate ILC2 population size will b

188 DP and CRTH2 play differential roles in UC.

189 this study we explored the possibility that CRTH2 plays a role in 15dPGJ2-mediated inhibition of NF-

190 ogous molecule expressed on TH2 lymphocytes (CRTh2)-positive basophils were measured by means of flow

191 psies of UC patients revealed an increase of CRTH2-positive cells in the colonic mucosa and high CRTH

192 s model of AR and suggest that antagonism of CRTH2 prevents the development of both the EPR and LPR a

193 homologous molecule expressed on Th2 cells (CRTH2) promotes chemotaxis and proinflammatory cytokine

194 ositive cells in the colonic mucosa and high CRTH2 protein content.

195 Lower CCR5/CRTH2 ratios were strongly associated with a lower value

196 QAW039 displayed high affinity for the human CRTh2 receptor (1.14 +/- 0.44 nM) expressed in Chinese h

197 Prostaglandin D2 (PGD2) acting at the CRTH2 receptor (chemoattractant receptor-homologous mole

198 irac displaced [3H]PGD2 binding at the mouse CRTH2 receptor (mCRTH2) with comparable affinity (Ki = 1

199 cking of the COX-1/2 or HPGDS enzymes or the CRTH2 receptor abolishes ILC2 responses.

200 cular mechanism involves CHI3L1 engaging the CRTH2 receptor and dampening beta-catenin signaling for

201 Treatment with the CRTH2 receptor antagonist prevented the decreases in RF

202 ut affecting endogenous PGD(2) production or CRTH2 receptor expression.

203 ed inflammatory response by signals from the Crth2 receptor in macrophages that lack Crth2 expression

204 analysis of arylacetic acid class NSAIDs as CRTH2 receptor ligands was performed.

205 The CRTH2 receptor shares greatest sequence similarity with

206 Crth2 receptor signaling down-regulates lipopolysacchari

207 d neuronal differentiation by activating the CRTH2 receptor, which triggers a downstream cascade invo

208 nts and Eol-1 cells was mediated through the CRTH2 receptor.

209 relatively slow dissociation from the human CRTh2 receptor.

210 e of its relatively slower off rate from the CRTh2 receptor.

211 gous molecules expressed on T-helper type 2 (CRTh2) receptor antagonists, including fevipiprant (NVP-

212 omologous molecule expressed on T(H)2 cells (CRTH2) receptor axis potently induces cytokine productio

213 -homologous molecule expressed on Th2 cells (CRTH2) receptor, a G protein-coupled receptor that media

214 dy provides the first clinical evidence that CRTH2 receptors contribute to airflow limitation, sympto

215 ceptor-like molecule expressed on Th2 cells (CRTH2) receptors.

216 Single nucleotide polymorphisms (SNPs) in CRTh2 (rs11571288, rs545659, rs634681) have been associa

217 These findings show an association between CRTh2 rs533116 and allergic asthma and suggest this may

218 Here, we assessed the association between CRTh2 rs533116 and allergic asthma, expression of CRTh2

219 CRTh2 rs533116 was associated with allergic asthma in Wh

220 CRTh2 rs533116 was genotyped in an ethnically diverse po

221 crease in the % of CD4(+) T cells expressing CRTh2 seen during the follow-up visit correlated with th

222 Interestingly, Crth2 signaling down-regulated the Ca(2+)-regulated heat

223 s assessed by stimulating Th2 cells with the CRTh2-specific agonist 13,14-dihydro-15-keto-PGD(2) (DK-

224 ast majority of cutaneous ILCs belong to the CRTH2(+) subset and reside in the upper skin layers.

225 The ratio between CCR5 and CRTH2 T cell frequencies was used to quantify type 1 (hi

226 acity (DLCO) was associated with higher CCR5/CRTH2 T cell ratios (Th1/Tc1) (P=0.009), while in those

227 Patients with SSc exhibited lower CCR5/CRTH2 T cell ratios than those exhibited by control subj

228 Markedly reduced CCR5/CRTH2 T cell ratios were observed in SSc patients with I

229 cytometry: CD4(+) T cells, Th2 cells (CD4(+) CRTh2(+) T cells and % of CD4(+) T cells expressing CRTh

230 IL-4 enhances the generation of CCR4(+) and CRTH2(+) T cells, and suppresses the generation of CXCR3

231 SP-D suppressed allergen-driven CD27(-)CD4(+)CRTh2(+) T-cell proliferation (P < 0.01), IL-4, and IL-5

232 hich consisted of T(H)2-like (CCR6(-)CXCR3(-)CRTH2(-)), T(H)2 (CCR6(-)CXCR3(-)CRTH2(+)CD161(-)), and

233 Along with increased IL-4 and GATA-3, CRTH2(+) Th cells isolated from Th2-skewed cultures or t

234 Tc1-specific), and prostaglandin D2 receptor CRTH2 (Th2/Tc2-specific).

235 m innate type 2 lymphocytes, NKT, and CD4(+) CRTH2(+) Th2 cells.

236 memory CD25(+)CD127(+)CD161(-)CD49d(+)CCR4(+)CRTH2(+) Th2 population was elevated at 6 months in urba

237 pressed CD44 and a larger fraction expressed CRTH2 than the controls.

238 tibodies (mAbs) against the PGD(2) receptor, CRTH2, the best selective Th2-cell surface marker to dat

239 Ramatroban, a dual CRTH2/thromboxane-like prostanoid receptor antagonist, m

240 hrough the G protein-coupled receptor (GPCR) CRTH2 to mediate various inflammatory responses.

241 okine receptors CCR3, CCR4, CCR5, CXCR3, and CRTh2, together with markers of memory phenotype (CD27 a

242 and correlated with decreased frequencies of CRTH2(+) Treg cells in EA patients.

243 The frequency of CRTH2(+) Tregs as decreased significantly in all the ast

244 ound to diminish the suppressive function of CRTH2(+) Tregs which partially normalized during high-al

245 Expression of CRTh2, type 2 cytokines and degree of apoptosis (Annexin

246 In contrast, CRTH2 was decreased in eosinophils, NK, and CD3(+) T cel

247 The proportion of cells expressing CRTh2 was determined in peripheral blood from subjects w

248 of the 2 inflammatory cell receptors DP1 and CRTH2 was evaluated on luminal cells.

249 Furthermore, PGD2 signaling via CRTH2 was found to diminish the suppressive function of

250 67 [1.09-6.55], P < 0.05), and expression of CRTh2 was higher in subjects with allergic airways disea

251 RNA was detected in amniocytes and myocytes, CRTH2 was not detectable at the protein level, as demons

252 cant reduction in cell surface expression of CRTh2 was observed between the placebo and active groups

253 +) T cells expressing the chemokine receptor CRTh2, we assessed the impact of Cat-PAD on the frequenc

254 nd the proportion of blood Th2 cells (CD4(+) CRTh2(+) ) were assessed in whole blood from subjects wi

255 chemoattractant receptor-homologous molecule(CRTH2), which is a G-protein-coupled receptor that is ex

256 interactions between CHI3L1 and the receptor CRTH2, which trafficked normally in BLOC-3 mutant HPS.